Melanie Davies

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7175321/publications.pdf

Version: 2024-02-01

		2970	2743
637	46,447	93	192
papers	citations	h-index	g-index
663	663	663	39402
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	COVID-19 vaccination uptake amongst ethnic minority communities in England: a linked study exploring the drivers of differential vaccination rates. Journal of Public Health, 2023, 45, e65-e74.	1.0	26
2	The feasibility of a self-management programme (My Life After Stroke; MLAS) for stroke survivors. Disability and Rehabilitation, 2023, 45, 235-243.	0.9	3
3	The development of a self-management intervention for stroke survivors – My Life After Stroke (MLAS). Disability and Rehabilitation, 2023, 45, 226-234.	0.9	4
4	Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials. Journal of Diabetes Science and Technology, 2023, 17, 1649-1661.	1.3	3
5	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21.	1.2	7
6	Individual, healthcare professional and systemâ€level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and metaâ€ethnography. Diabetic Medicine, 2022, 39, e14678.	1.2	10
7	Chronotype and wellâ€being in adults with established type 2 diabetes: A crossâ€sectional study. Diabetic Medicine, 2022, 39, e14690.	1.2	6
8	Gastrointestinal tolerability of onceâ€weekly semaglutide 2.4Âmg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, 2022, 24, 94-105.	2.2	34
9	Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin) Tj ETQq1 1 0).784314 r _{ 2.2	gBT /Overlock 1
10	trial. Diabetes, Obesity and Metabolism, 2022, 24, 34-41. Energy intake and weight during the <scp>COVID</scp> â€19 lockdown were not altered in a sample of older adults with type 2 diabetes in <scp>England</scp> . Diabetes, Obesity and Metabolism, 2022, 24, 546-549.	2.2	3
11	A systematic review and meta-analysis to compare the prevalence of depression between people with and without Type 1 and Type 2 diabetes. Primary Care Diabetes, 2022, 16, 1-10.	0.9	56
12	Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 2022, 134, 14-19.	0.9	46
13	Type 2 Diabetes and Impaired Physical Function: A Growing Problem. International Journal of Diabetology, 2022, 3, 30-45.	0.9	18
14	From the United Kingdom to Australia—Adapting a Web-Based Self-management Education Program to Support the Management of Type 2 Diabetes: Tutorial. Journal of Medical Internet Research, 2022, 24, e26339.	2.1	1
15	COVID-19 vaccine uptake and hesitancy opinions from frontline health care and social care workers: Survey data from 37 countries. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102361.	1.8	16
16	Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England. Cardiovascular Diabetology, 2022, 21, 8.	2.7	3
17	OUP accepted manuscript. Journal of Public Health, 2022, , .	1.0	0
18	A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. Nature Communications, 2022, 13, 624.	5.8	29

#	Article	IF	CITATIONS
19	Attitudes of older adults and their carers towards deâ€prescribing: A systematic review. Diabetic Medicine, 2022, 39, e14801.	1.2	12
20	Association between household size and COVID-19: A UK Biobank observational study. Journal of the Royal Society of Medicine, 2022, 115, 138-144.	1.1	14
21	Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis. World Journal of Diabetes, 2022, 13, 260-271.	1.3	3
22	The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study. International Journal of Cardiovascular Imaging, 2022, 38, 2013-2023.	0.7	2
23	Screening for type 2 diabetes after a diagnosis of gestational diabetes by ethnicity: A retrospective cohort study. Primary Care Diabetes, 2022, 16, 445-451.	0.9	2
24	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. Diabetes Care, 2022, 45, 1132-1140.	4.3	4
25	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. Endocrinology, Diabetes and Metabolism, 2022, 5, e00330.	1.0	9
26	Structured diabetes selfâ€management education and glycaemic control in lowâ€and middleâ€income countries: A systematic review. Diabetic Medicine, 2022, 39, e14812.	1.2	13
27	Ethnic differences in the relationship between step cadence and physical function in older adults. Journal of Sports Sciences, 2022, 40, 1183-1190.	1.0	0
28	Cardiovascular and renal outcomes of initial combination therapy with glucoseâ€lowering agents versus a stepwise approach in newly diagnosed or treatmentâ€naà ve type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1469-1482.	2.2	0
29	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension. Diabetes, Obesity and Metabolism, 2022, 24, 1553-1564.	2.2	151
30	Relative protein intake and associations with markers of physical function in those with type 2 diabetes. Diabetic Medicine, 2022, 39, e14851.	1.2	4
31	The effects of empagliflozin, dietary energy restriction, or both on appetiteâ€regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The ⟨scp⟩SEESAW⟨/scp⟩ randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1509-1521.	2.2	5
32	Investigation of a UK biobank cohort reveals causal associations of self-reported walking pace with telomere length. Communications Biology, 2022, 5, 381.	2.0	17
33	The Effects of Omega-3 Supplementation on Depression in Adults with Cardiometabolic Disease: A Systematic Review of Randomised Control Trials. Nutrients, 2022, 14, 1827.	1.7	2
34	Nonâ€inferiority and clinical superiority of glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transporterâ€2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1598-1606.	2.2	3
35	Fibroâ€inflammatory recovery and type 2 diabetes remission following a low calorie diet but not exercise training: A secondary analysis of the ⟨scp⟩DIASTOLIC⟨/scp⟩ randomised controlled trial. Diabetic Medicine, 2022, 39, e14884.	1.2	4
36	Estimates of years of life lost depended on the method used: tutorial and comparative investigation. Journal of Clinical Epidemiology, 2022, 150, 42-50.	2.4	7

#	Article	IF	Citations
37	Mortality risk comparing walking pace to handgrip strength and a healthy lifestyle: A UK Biobank study. European Journal of Preventive Cardiology, 2021, 28, 704-712.	0.8	25
38	Wrist-worn accelerometers: recommending \sim 1.0 m <i>g</i> as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults. British Journal of Sports Medicine, 2021, 55, 814-815.	3.1	32
39	Self-Compassion, Metabolic Control and Health Status in Individuals with Type 2 Diabetes: A UK Observational Study. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 413-419.	0.6	13
40	The impact of obesity on severe disease and mortality in people with SARSâ€CoVâ€2: A systematic review and metaâ€analysis. Endocrinology, Diabetes and Metabolism, 2021, 4, e00176.	1.0	87
41	Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A realâ€world study of patients followed for up to 19 years. Diabetes, Obesity and Metabolism, 2021, 23, 218-227.	2.2	10
42	Empagliflozin treatment effects across categories of baseline <scp>HbA1c</scp> , body weight and blood pressure as an addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 425-433.	2.2	19
43	Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S Diabetes Care, 2021, 44, 231-239.	4.3	26
44	A cost comparison of an enhanced primary care diabetes service and standard care. Primary Care Diabetes, 2021, 15, 601-606.	0.9	3
45	Risk of cancer incidence and mortality associated with diabetes: A systematic review with trend analysis of 203 cohorts. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 14-22.	1.1	33
46	Improvements in Glycemic Control After Acute Moderate-Intensity Continuous or High-Intensity Interval Exercise Are Greater in South Asians Than White Europeans With Nondiabetic Hyperglycemia: A Randomized Crossover Study. Diabetes Care, 2021, 44, 201-209.	4.3	6
47	Association of Timing and Balance of Physical Activity and Rest/Sleep With Risk of COVID-19: A UK Biobank Study. Mayo Clinic Proceedings, 2021, 96, 156-164.	1.4	30
48	Use of MyDesmond digital education programme to support selfâ€management in people with type 2 diabetes during the COVIDâ€19 pandemic. Diabetic Medicine, 2021, 38, e14469.	1.2	17
49	Deviceâ€measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabetic Medicine, 2021, 38, e14393.	1.2	17
50	Comparing 24 h physical activity profiles: Office workers, women with a history of gestational diabetes and people with chronic disease condition(s). Journal of Sports Sciences, 2021, 39, 219-226.	1.0	8
51	Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the <scp>LYDIA</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1409-1414.	2.2	10
52	Effectiveness of the Transformation model, a model of care that integrates diabetes services across primary, secondary and community care: A retrospective study. Diabetic Medicine, 2021, 38, e14504.	1.2	2
53	Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Diabetes Care, 2021, 44, 915-924.	4.3	16
54	Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136. Diabetes Care, 2021, 44, e61-e61.	4.3	0

#	Article	IF	Citations
55	Rates and estimated cost of primary care consultations in people diagnosed with type 2 diabetes and comorbidities: A retrospective analysis of 8.9 million consultations. Diabetes, Obesity and Metabolism, 2021, 23, 1301-1310.	2.2	5
56	Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank. International Journal of Obesity, 2021, 45, 1155-1159.	1.6	43
57	Physical Activity after Cardiac EventS (PACES): a group education programme with subsequent text message support designed to increase physical activity in individuals with diagnosed coronary heart disease: a randomised controlled trial. Open Heart, 2021, 8, e001351.	0.9	4
58	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	3.2	36
59	Improved diabetesâ€related distress and selfâ€efficacy outcomes in a selfâ€management digital programme for people with type 2 diabetes, myDESMOND. Diabetic Medicine, 2021, 38, e14551.	1.2	4
60	In-shoe pressure thresholds for people with diabetes and neuropathy at risk of ulceration: A systematic review. Journal of Diabetes and Its Complications, 2021, 35, 107815.	1,2	9
61	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVIDâ€19: Analysis of the ISARIC CCPâ€UK Cohort. Obesity, 2021, 29, 1223-1230.	1.5	34
62	Concurrent screen use and crossâ€sectional association with lifestyle behaviours and psychosocial health in adolescent females. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2164-2170.	0.7	5
63	The impact of COVIDâ€19 restrictions on accelerometerâ€assessed physical activity and sleep in individuals with type 2 diabetes. Diabetic Medicine, 2021, 38, e14549.	1.2	22
64	Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, 384, 989-1002.	13.9	1,374
65	Evaluation of an 8-Week Vegan Diet on Plasma Trimethylamine-N-Oxide and Postchallenge Glucose in Adults with Dysglycemia or Obesity. Journal of Nutrition, 2021, 151, 1844-1853.	1.3	20
66	Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation. European Journal of Public Health, 2021, 31, 630-634.	0.1	20
67	Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 971-984.	6.3	429
68	Association of working shifts, inside and outside of healthcare, with severe COVIDâ [^] 19: an observational study. BMC Public Health, 2021, 21, 773.	1,2	19
69	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 325, 1403.	3.8	387
70	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 325, 1414.	3.8	413
71	Long COVID â€" metabolic risk factors and novel therapeutic management. Nature Reviews Endocrinology, 2021, 17, 379-380.	4.3	38
72	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). Journal of the Endocrine Society, 2021, 5, A10-A10.	0.1	0

#	Article	IF	Citations
73	Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4). Journal of the Endocrine Society, 2021, 5, A63-A64.	0.1	1
74	Cardiovascular effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: The <i>P</i> value and beyond. Diabetes, Obesity and Metabolism, 2021, 23, 1685-1691.	2.2	4
75	Device-assessed total and prolonged sitting time: associations with anxiety, depression, and health-related quality of life in adults. Journal of Affective Disorders, 2021, 287, 107-114.	2.0	17
76	Microvascular Disease and Risk of Cardiovascular Events and Death From Intensive Treatment in Type 2 Diabetes. Mayo Clinic Proceedings, 2021, 96, 1458-1469.	1.4	10
77	Promoting physical activity in a multi-ethnic population at high risk of diabetes: the 48-month PROPELS randomised controlled trial. BMC Medicine, 2021, 19, 130.	2.3	14
78	Modelling the Reallocation of Time Spent Sitting into Physical Activity: Isotemporal Substitution vs. Compositional Isotemporal Substitution. International Journal of Environmental Research and Public Health, 2021, 18, 6210.	1.2	8
79	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 503-515.	13.9	668
80	Effect of exercise on sleep and bi-directional associations with accelerometer-assessed physical activity in men with obesity. Applied Physiology, Nutrition and Metabolism, 2021, 46, 597-605.	0.9	3
81	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. BMC Infectious Diseases, 2021, 21, 717.	1.3	19
82	Use of the socio-ecological model to explore factors that influence the implementation of a diabetes structured education programme (EXTEND project) inLilongwe, Malawi and Maputo, Mozambique: a qualitative study. BMC Public Health, 2021, 21, 1355.	1,2	10
83	Clustering of comorbidities. Future Healthcare Journal, 2021, 8, e224-e229.	0.6	17
84	Pâ€"384 First trimester pregnancy outcomes after confirmed SARS-CoVâ€"2 infection in the community; a nationwide prospective longitudinal study of 10,000 pregnant women from the COVIDâ€"19 pandemic. Human Reproduction, 2021, 36, .	0.4	0
85	Pâ€"712 Ovulation induction in type 1 anovulation: a comparative study using gonadotrophins and the GnRH pump. Human Reproduction, 2021, 36, .	0.4	0
86	Ethnic, social and multimorbidity disparities in therapeutic inertia: A <scp>UK</scp> primary care observational study in patients newly diagnosed with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2437-2445.	2.2	7
87	Using observational data to prioritise COVID-19 vaccination strategies: opportunity or necessity?. Public Health, 2021, 197, e20.	1.4	0
88	Promoting physical activity with self-management support for those with multimorbidity: a randomised controlled trial. British Journal of General Practice, 2021, 71, e921-e930.	0.7	4
89	EXTending availability of self-management structured EducatioN programmes for people with type 2 Diabetes in low-to-middle income countries (EXTEND)â€"a feasibility study in Mozambique and Malawi. BMJ Open, 2021, 11, e047425.	0.8	3
90	Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K BMC Infectious Diseases, 2021, 21, 908.	1.3	41

#	Article	IF	Citations
91	Prevention of Microvascular Complications of Diabetes. Endocrinology and Metabolism Clinics of North America, 2021, 50, 431-455.	1.2	25
92	Normative wrist-worn accelerometer values for self-paced walking and running: a walk in the park. Journal of Sports Sciences, 2021, , 1-8.	1.0	4
93	Feature selection for unsupervised machine learning of accelerometer data physical activity clusters – A systematic review. Gait and Posture, 2021, 90, 120-128.	0.6	19
94	Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 997-1007.	1.2	18
95	2â€fEfficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adults With Overweight or Obesity (STEP 1). Adipositas - Ursachen Folgeerkrankungen Therapie, 2021, 15, .	0.2	O
96	3â€fEfficacy and Safety of Semaglutide 2.4 mg Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2). Adipositas - Ursachen Folgeerkrankungen Therapie, 2021, 15, .	0.2	0
97	The importance of physical activity in management of type 2 diabetes and COVID-19. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110546.	1.4	16
98	Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT. Health Technology Assessment, 2021, 25, 1-190.	1.3	7
99	Promoting inclusion in clinical trialsâ€"a rapid review of the literature and recommendations for action. Trials, 2021, 22, 880.	0.7	65
100	Metabolic Effects of Breaking Prolonged Sitting With Standing or Light Walking in Older South Asians and White Europeans: A Randomized Acute Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 139-146.	1.7	51
101	Emerging glucose-lowering therapies: a guide for cardiologists. Heart, 2020, 106, 18-23.	1.2	6
102	Prediction of Diabetic Foot Ulceration: The Value of Using Microclimate Sensor Arrays. Journal of Diabetes Science and Technology, 2020, 14, 55-64.	1.3	11
103	Walking pace improves all-cause and cardiovascular mortality risk prediction: A UK Biobank prognostic study. European Journal of Preventive Cardiology, 2020, 27, 1036-1044.	0.8	29
104	The Microalbuminuria Education Medication and Optimisation (MEMO) study: 4 years followâ€up of multifactorial intervention in highâ€risk individuals with type 2 diabetes. Diabetic Medicine, 2020, 37, 286-297.	1,2	5
105	Leisureâ€time physical activity and life expectancy in people with cardiometabolic multimorbidity and depression. Journal of Internal Medicine, 2020, 287, 87-99.	2.7	23
106	Increasing patient activation through diabetes self-management education: Outcomes of DESMOND in regional Western Australia. Patient Education and Counseling, 2020, 103, 848-853.	1.0	25
107	Predictors of the Acute Postprandial Response to Breaking Up Prolonged Sitting. Medicine and Science in Sports and Exercise, 2020, 52, 1385-1393.	0.2	13
108	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	0.9	12

#	Article	IF	CITATIONS
109	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 221-228.	2.9	368
110	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 487-493.	4.3	846
111	Qualitative evaluation of A Safer Ramadan, a structured education programme that addresses the safer observance of Ramadan for Muslims with Type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 160, 107979.	1.1	8
112	activPAL and ActiGraph Assessed Sedentary Behavior and Cardiometabolic Health Markers. Medicine and Science in Sports and Exercise, 2020, 52, 391-397.	0.2	18
113	Maturational timing, physical self-perceptions and physical activity in UK adolescent females: investigation of a mediated effects model. Annals of Human Biology, 2020, 47, 384-390.	0.4	5
114	Dysglycaemia and South Asian ethnicity: a proteomic discovery and confirmation analysis highlights differences in ZAG. Journal of Proteins and Proteomics, 2020, 11, 259-268.	1.0	0
115	Multimorbidity and SARS-CoV-2 infection in UK Biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 775-776.	1.8	15
116	Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes. Diabetes Care, 2020, 43, 2248-2256.	4.3	25
117	Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study. EClinicalMedicine, 2020, 25, 100466.	3.2	129
118	Prediction of type 2 diabetes risk in people with non-diabetic hyperglycaemia: model derivation and validation using UK primary care data. BMJ Open, 2020, 10, e037937.	0.8	2
119	First-line treatment for type 2 diabetes: is it too early to abandon metformin?. Lancet, The, 2020, 396, 1705-1707.	6.3	22
120	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Annals of Internal Medicine, 2020, 172, 541.	2.0	53
121	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. Pharmaceuticals, 2020, 13, 427.	1.7	14
122	COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 2241-2243.	1.8	5
123	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet, The, 2020, 396, 2019-2082.	6.3	327
124	Comparative effectiveness of gliclazide modified release versus sitagliptin as secondâ€line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2417-2426.	2.2	13
125	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the <scp>CANVAS</scp> Program. Diabetes, Obesity and Metabolism, 2020, 22, 2199-2203.	2.2	5
126	Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia, 2020, 63, 2129-2139.	2.9	15

#	Article	IF	CITATIONS
127	Physical behaviors and chronotype in people with type 2 diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001375.	1.2	28
128	Effectiveness of the Ready to Reduce Risk (3R) complex intervention for the primary prevention of cardiovascular disease: a pragmatic randomised controlled trial. BMC Medicine, 2020, 18, 198.	2.3	6
129	Healthy lifestyle and life expectancy in people with multimorbidity in the UK Biobank: A longitudinal cohort study. PLoS Medicine, 2020, 17, e1003332.	3.9	143
130	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. Lancet Diabetes and Endocrinology,the, 2020, 8, 810-811.	5 . 5	4
131	Prospectively Reallocating Sedentary Time: Associations with Cardiometabolic Health. Medicine and Science in Sports and Exercise, 2020, 52, 844-850.	0.2	13
132	Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care, 2020, 43, 2313-2322.	4.3	95
133	Toe gaps and their assessment in footwear for people with diabetes: a narrative review. Journal of Foot and Ankle Research, 2020, 13, 70.	0.7	1
134	Effects of an Electronic Software "Prompt―With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial. Diabetes Care, 2020, 43, 1893-1901.	4.3	2
135	Number needed to treat in cardiovascular outcome trials of glucagonâ€ike peptideâ€1 receptor agonists: A systematic review with temporal analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1670-1677.	2.2	9
136	Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 569-575.	2.6	16
137	Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Research and Care, 2020, 8, e001248.	1.2	65
138	Reducing sitting at work: process evaluation of the SMArT Work (Stand More At Work) intervention. Trials, 2020, 21, 403.	0.7	17
139	Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ, The, 2020, 369, m1361.	3.0	485
140	Cardiovascular outcome trials of glucose-lowering therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 237-249.	0.7	5
141	Obesity and risk of COVID-19: analysis of UK biobank. Primary Care Diabetes, 2020, 14, 566-567.	0.9	69
142	Patientâ€reported outcomes after 10â€year followâ€up of intensive, multifactorial treatment in individuals with screenâ€detected type 2 diabetes: the ADDITIONâ€Europe trial. Diabetic Medicine, 2020, 37, 1509-1518.	1.2	1
143	Prevalence of coâ€morbidities and their association with mortality in patients with <scp>COVID</scp> â€19: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1915-1924.	2.2	320
144	Health impacts of seated arm ergometry training in patients with a diabetic foot ulcer: protocol for a randomised controlled trial. BMJ Open, 2020, 10, e039062.	0.8	3

#	Article	IF	Citations
145	Adults with early-onset type 2 diabetes (aged 18–39Âyears) are severely underrepresented in diabetes clinical research trials. Diabetologia, 2020, 63, 1516-1520.	2.9	15
146	Application of normalisation process theory in understanding implementation processes in primary care settings in the UK: a systematic review. BMC Family Practice, 2020, 21, 52.	2.9	45
147	A randomized, openâ€label, active comparator trial assessing the effects of 26â€‱weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	2.2	13
148	Body mass index and the risk of <scp>COVID</scp> â€19 across ethnic groups: Analysis of <scp>UK</scp> Biobank. Diabetes, Obesity and Metabolism, 2020, 22, 1953-1954.	2.2	27
149	COVID-19 cumulative mortality rates for frontline healthcare staff in England. British Journal of General Practice, 2020, 70, 327.2-328.	0.7	17
150	Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care, 2020, 43, 2128-2136.	4.3	10
151	Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 965-967.	1.8	390
152	Influence of sociodemographic characteristics on the preferred format of health education delivery in individuals with type 2 diabetes mellitus and or cardiovascular disease: a questionnaire study. Diabetic Medicine, 2020, 37, 982-990.	1.2	11
153	A Cost and Cost-Benefit Analysis of the Stand More AT Work (SMArT Work) Intervention. International Journal of Environmental Research and Public Health, 2020, 17, 1214.	1.2	19
154	Efficacy and tolerability of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1035-1046.	2.2	46
155	FilterK: A new outlier detection method for k-means clustering of physical activity. Journal of Biomedical Informatics, 2020, 104, 103397.	2.5	17
156	Pragmatic management of lowâ€energy diets in people with type 2 diabetes in primary care: a decision aid for clinicians. Diabetic Medicine, 2020, 37, 747-751.	1.2	3
157	Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naà ve patients with type 2 diabetes: initial triple study. BMJ Open Diabetes Research and Care, 2020, 8, e000807.	1.2	13
158	The present and future scope of realâ€world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future? Diabetes, Obesity and Metabolism, 2020, 22, 21-34.	2.2	16
159	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism: Clinical and Experimental, 2020, 107, 154242.	1.5	17
160	Effects of Low-Energy Diet or Exercise on Cardiovascular Function in Working-Age Adults With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded End Point Trial. Diabetes Care, 2020, 43, 1300-1310.	4.3	52
161	Physical activity and lipidomics in a population at high risk of type 2 diabetes mellitus. Journal of Sports Sciences, 2020, 38, 1150-1160.	1.0	7
162	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 2020, 28, 1050-1061.	1.5	148

#	Article	IF	CITATIONS
163	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ Open, 2020, 10, e034137.	0.8	5
164	Using Intervention Mapping to Develop a Digital Self-Management Program for People With Type 2 Diabetes: Tutorial on MyDESMOND. Journal of Medical Internet Research, 2020, 22, e17316.	2.1	24
165	Virtual Consultations and the Role of Technology During the COVID-19 Pandemic for People With Type 2 Diabetes: The UK Perspective. Journal of Medical Internet Research, 2020, 22, e21609.	2.1	45
166	Perceptions of healthcare professionals and people with type 2 diabetes on emotional support: a qualitative study. BJGP Open, 2020, 4, bjgpopen20X101018.	0.9	5
167	Equivalency of Sleep Estimates: Comparison of Three Research-Grade Accelerometers. Journal for the Measurement of Physical Behaviour, 2020, 3, 294-303.	0.5	13
168	Title is missing!. , 2020, 17, e1003332.		0
169	Title is missing!. , 2020, 17, e1003332.		0
170	Title is missing!. , 2020, 17, e1003332.		0
171	Title is missing!. , 2020, 17, e1003332.		0
172	Title is missing!. , 2020, 17, e1003332.		0
173	Title is missing!. , 2020, 17, e1003332.		0
174	Title is missing!. , 2020, 17, e1003332.		0
175	Title is missing!. , 2020, 17, e1003332.		O
176	Prevalence and progression of diabetic nephropathy in South Asian, white European and African Caribbean people with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 658-673.	2.2	15
177	Online patient education interventions in type 2 diabetes or cardiovascular disease: A systematic review of systematic reviews. Primary Care Diabetes, 2019, 13, 16-27.	0.9	23
178	Micro-costing and a cost-consequence analysis of the  Girls Active' programme: A cluster randomised controlled trial. PLoS ONE, 2019, 14, e0221276.	1.1	5
179	Relevance of physical function in the association of red and processed meat intake with all–cause, cardiovascular, and cancer mortality. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1308-1315.	1.1	11
180	Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881986159.	1.4	16

#	Article	IF	CITATIONS
181	Evaluation and refinement of the PRESTARt tool for identifying 12–14 year olds at high lifetime risk of developing type 2 diabetes compared to a clinicians assessment of risk: a cross-sectional study. BMC Endocrine Disorders, 2019, 19, 79.	0.9	4
182	Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes and Endocrinology, the, 2019, 7, 938-948.	5.5	240
183	Towards a Portable Model to Discriminate Activity Clusters from Accelerometer Data. Sensors, 2019, 19, 4504.	2.1	8
184	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN $1\hat{a}\in$ "7 trials. Diabetes and Metabolism, 2019, 45, 409-418.	1.4	114
185	A data-driven, meaningful, easy to interpret, standardised accelerometer outcome variable for global surveillance. Journal of Science and Medicine in Sport, 2019, 22, 1132-1138.	0.6	32
186	Impact of Depression and Anxiety on Change to Physical Activity Following a Pragmatic Diabetes Prevention Program Within Primary Care: Pooled Analysis From Two Randomized Controlled Trials. Diabetes Care, 2019, 42, 1847-1853.	4.3	22
187	The right place for Sulphonylureas today: Part of †Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus'. Diabetes Research and Clinical Practice, 2019, 157, 107836.	1.1	23
188	Process evaluation of the school-based Girls Active programme. BMC Public Health, 2019, 19, 1187.	1.2	19
189	A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes. Journal of Diabetes Science and Technology, 2019, 13, 881-889.	1.3	19
190	A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy. Diabetes, Obesity and Metabolism, 2019, 21, 1101-1110.	2.2	6
191	Glycaemic benefit of iGlarLixi in insulinâ€naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLanâ€O randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 1967-1972.	2.2	14
192	A fitting problem: Standardising shoe fit standards to reduce related diabetic foot ulcers. Diabetes Research and Clinical Practice, 2019, 154, 66-74.	1.1	7
193	Improved treatment satisfaction in patients with type 2 diabetes treated with onceâ€weekly semaglutide in the SUSTAIN trials. Diabetes, Obesity and Metabolism, 2019, 21, 2315-2326.	2.2	13
194	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes, Obesity and Metabolism, 2019, 21, 2203-2210.	2.2	55
195	Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study. BMC Medicine, 2019, 17, 108.	2.3	149
196	Comparative Relevance of Physical Fitness and Adiposity on Life Expectancy. Mayo Clinic Proceedings, 2019, 94, 985-994.	1.4	42
197	Association of depression and anxiety with clinical, sociodemographic, lifestyle and environmental factors in South Asian and white European individuals at high risk of diabetes. Diabetic Medicine, 2019, 36, 1158-1167.	1.2	4
198	Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the) Tj ETQq0 0 0 rgB	T/ 0. ærlod	ck 110 Tf 50 57

#	Article	IF	CITATIONS
199	Effectiveness of psychoeducational interventions for the treatment of diabetes-specific emotional distress and glycaemic control in people with type 2 diabetes: A systematic review and meta-analysis. Primary Care Diabetes, 2019, 13, 556-567.	0.9	24
200	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA - Journal of the American Medical Association, 2019, 321, 1466.	3.8	233
201	Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12â€month prospective observational study. Diabetes, Obesity and Metabolism, 2019, 21, 1585-1595.	2.2	19
202	Take Control: A randomized trial evaluating the efficacy and safety of self†versus physicianâ€managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1615-1624.	2.2	33
203	Efficacy of low―and veryâ€lowâ€energy diets in people with type 2 diabetes mellitus: A systematic review and metaâ€analysis of interventional studies. Diabetes, Obesity and Metabolism, 2019, 21, 1695-1705.	2.2	15
204	Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica, 2019, 56, 839-850.	1.2	28
205	Differences in objectively measured physical activity and sedentary behaviour between white Europeans and south Asians recruited from primary care: cross-sectional analysis of the PROPELS trial. BMC Public Health, 2019, 19, 95.	1.2	24
206	Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study. BMJ Open, 2019, 9, e027773.	0.8	22
207	Rationale and methods for the Exercise for Type 1 Diabetes Education program: a pilot randomized controlled trial of an education program to support adults with type 1 diabetes mellitus (T1DM) to undertake exercise. BMJ Open Diabetes Research and Care, 2019, 7, e000693.	1.2	1
208	Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 925-937.	5 . 5	39
209	Activity Intensity, Volume, and Norms: Utility and Interpretation of Accelerometer Metrics. Medicine and Science in Sports and Exercise, 2019, 51, 2410-2422.	0.2	39
210	Should sodiumâ€glucose coâ€transporterâ€2 inhibitors be considered as firstâ€line oral therapy for people with type 2 diabetes? Diabetes, Obesity and Metabolism, 2019, 21, 207-209.	2.2	4
211	Cardiovascular, cancer and mortality events after bariatric surgery in people with and without pre $\hat{a} \in \mathbb{R}$ presiting diabetes: A nationwide study. Journal of Diabetes, 2019, 11, 265-272.	0.8	3
212	Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis. Acta Diabetologica, 2019, 56, 331-339.	1.2	18
213	Reply to Mantovani: "Causality between nonâ€alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes― Liver International, 2019, 39, 780-781.	1.9	0
214	Postpartum monitoring of women with a history of gestational diabetes â€" A cross-sectional study of an inner-city population. Primary Care Diabetes, 2019, 13, 376-379.	0.9	7
215	Cardiovascular efficacy and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: a systematic review and network metaâ€analysis. Diabetic Medicine, 2019, 36, 444-452.	1.2	30
216	Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs, 2019, 79, 173-186.	4.9	13

#	Article	IF	Citations
217	Causality between nonâ€alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A metaâ€analysis with bias analysis. Liver International, 2019, 39, 557-567.	1.9	62
218	Meta-analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. British Journal of Surgery, 2019, 106, 181-189.	0.1	33
219	Glycaemic management of type 2 diabetes. Medicine, 2019, 47, 32-39.	0.2	6
220	Multimorbidity and lifestyle factors among adults with intellectual disabilities: a crossâ€sectional analysis of a UK cohort. Journal of Intellectual Disability Research, 2019, 63, 255-265.	1.2	40
221	Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. British Journal of Psychiatry, 2019, 214, 63-73.	1.7	77
222	Providing a Basis for Harmonization of Accelerometer-Assessed Physical Activity Outcomes Across Epidemiological Datasets. Journal for the Measurement of Physical Behaviour, 2019, 2, 131-142.	0.5	27
223	Enhancing the value of accelerometer-assessed physical activity: meaningful visual comparisons of data-driven translational accelerometer metrics. Sports Medicine - Open, 2019, 5, 47.	1.3	40
224	A school-based intervention (â€~Girls Active') to increase physical activity levels among 11- to 14-year-old girls: cluster RCT. Public Health Research, 2019, 7, 1-162.	0.5	14
225	A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinology and Metabolism, 2019, 34, 247.	1.3	64
226	The impact of neighbourhood walkability on the effectiveness of a structured education programme to increase objectively measured walking. Journal of Public Health, 2018, 40, 82-89.	1.0	2
227	Realâ€world evaluation of the DESMOND type 2 diabetes education and selfâ€management programme. Practical Diabetes, 2018, 35, 19.	0.1	13
228	Sleep duration, obesity and insulin resistance in a multi-ethnic UK population at high risk of diabetes. Diabetes Research and Clinical Practice, 2018, 139, 195-202.	1.1	40
229	Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes and Endocrinology,the, 2018, 6, 821-832.	5.5	83
230	Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. Diabetes, 2018, 67, 1395-1400.	0.3	36
231	Type 2 diabetes – Authors' reply. Lancet, The, 2018, 391, 1262.	6.3	6
232	What have we learnt from "real world―data, observational studies and metaâ€analyses. Diabetes, Obesity and Metabolism, 2018, 20, 47-58.	2.2	35
233	Beyond Cut Points: Accelerometer Metrics that Capture the Physical Activity Profile. Medicine and Science in Sports and Exercise, 2018, 50, 1323-1332.	0.2	114
234	Sedentary Behaviour, Diabetes, and the Metabolic Syndrome. Springer Series on Epidemiology and Public Health, 2018, , 193-214.	0.5	0

#	Article	IF	CITATIONS
235	Sedentary Time and MRIâ€Derived Measures of Adiposity in Active Versus Inactive Individuals. Obesity, 2018, 26, 29-36.	1.5	17
236	Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation. Journal of Sports Sciences, 2018, 36, 1586-1593.	1.0	20
237	Effectiveness of the †Girls Active†school-based physical activity programme: A cluster randomised controlled trial. International Journal of Behavioral Nutrition and Physical Activity, 2018, 15, 40.	2.0	47
238	Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. Diabetologia, 2018, 61, 1592-1602.	2.9	26
239	Screening for Diabetes and Prediabetes. Endocrinology, 2018, , 1-33.	0.1	1
240	Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis, 2018, 271, 223-231.	0.4	13
241	Development of a multi-component lifestyle intervention for preventing type 2 diabetes and cardiovascular risk factors in adults with intellectual disabilities. Journal of Public Health, 2018, 40, e141-e150.	1.0	11
242	Associations Between Sedentary Behaviors and Cognitive Function: Cross-Sectional and Prospective Findings From the UK Biobank. American Journal of Epidemiology, 2018, 187, 441-454.	1.6	64
243	Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes and Endocrinology,the, 2018, 6, 266-268.	5 . 5	26
244	Accelerometer-assessed Physical Activity in Epidemiology. Medicine and Science in Sports and Exercise, 2018, 50, 257-265.	0.2	115
245	Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes and Endocrinology, the, 2018, 6, 130-142.	5.5	233
246	Liraglutide and cardiovascular outcomes in adults with overweight or obesity: <scp>A</scp> <i>post hoc</i> analysis from <scp>SCALE</scp> randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 734-739.	2.2	71
247	Reaction time, cardiorespiratory fitness and mortality in UK Biobank: An observational study. Intelligence, 2018, 66, 79-83.	1.6	4
248	Structured education programme for women with polycystic ovary syndrome: a randomised controlled trial. Endocrine Connections, 2018, 7, 26-35.	0.8	15
249	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. American Journal of Cardiovascular Drugs, 2018, 18, 13-24.	1.0	4
250	Compliance of Adolescent Girls to Repeated Deployments of Wrist-Worn Accelerometers. Medicine and Science in Sports and Exercise, 2018, 50, 1508-1517.	0.2	22
251	Technology and chronic disease management – Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 91-92.	5.5	0
252	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. BMJ Open, 2018, 8, e023206.	0.8	4

#	Article	IF	Citations
253	Baby Steps $\hat{a} \in \hat{a}$ a structured group education programme with accompanying mobile web application designed to promote physical activity in women with a history of gestational diabetes: study protocol for a randomised controlled trial. Trials, 2018, 19, 682.	0.7	11
254	Physical Activity after Cardiac EventS (PACES) $\hat{a} \in \hat{a}$ a group education programme with subsequent text-message support designed to increase physical activity in individuals with diagnosed coronary heart disease: study protocol for a randomised controlled trial. Trials, 2018, 19, 537.	0.7	12
255	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	2.9	1,002
256	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41, 2669-2701.	4.3	2,190
257	Effectiveness of the Stand More AT (SMArT) Work intervention: cluster randomised controlled trial. BMJ: British Medical Journal, 2018, 363, k3870.	2.4	137
258	Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. Diabetes Research and Clinical Practice, 2018, 146, 76-84.	1.1	12
259	Body mass index and mortality in people with and without diabetes: A UK Biobank study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1208-1216.	1.1	4
260	Screening for Diabetes and Prediabetes. Endocrinology, 2018, , 369-400.	0.1	2
261	Associations of Physical Behaviours and Behavioural Reallocations with Markers of Metabolic Health: A Compositional Data Analysis. International Journal of Environmental Research and Public Health, 2018, 15, 2280.	1.2	46
262	Movement through Active Personalised engagement (MAP) $\hat{a} \in$ a self-management programme designed to promote physical activity in people with multimorbidity: study protocol for a randomised controlled trial. Trials, 2018, 19, 576.	0.7	6
263	A three arm cluster randomised controlled trial to test the effectiveness and cost-effectiveness of the SMART Work & Life intervention for reducing daily sitting time in office workers: study protocol. BMC Public Health, 2018, 18, 1120.	1.2	25
264	Accurate diagnosis of diabetes mellitus and new paradigms of classification. Nature Reviews Endocrinology, 2018, 14, 386-387.	4.3	11
265	Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. Diabetes Care, 2018, 41, 1312-1320.	4.3	81
266	Patterns of Multimorbidity in Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. Mayo Clinic Proceedings, 2018, 93, 857-866.	1.4	105
267	Assessing the effectiveness of a goal-setting session as part of a structured group self-management education programme for people with type 2 diabetes. Patient Education and Counseling, 2018, 101, 2125-2133.	1.0	10
268	Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2169-2178.	2.2	40
269	Stand More AT Work (SMArT Work): using the behaviour change wheel to develop an intervention to reduce sitting time in the workplace. BMC Public Health, 2018, 18, 319.	1.2	76
270	Physical activity and structured exercise in patients with type 2 diabetes mellitus and heart failure. Practical Diabetes, 2018, 35, 131.	0.1	2

#	Article	IF	CITATIONS
271	Elevated Levels of Alpha Cells Emanating from the Pancreatic Ducts of a Patient with a Low BMI and Chronic Pancreatitis. Cell Transplantation, 2018, 27, 902-906.	1.2	3
272	Comparison of glucoseâ€lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 985-997.	2.2	23
273	Management of hyperglycaemia in type 2 diabetes: the 2018 consensus report by ADA/EASD Insights from one of the authors. British Journal of Diabetes, 2018, 18, 137-140.	0.1	6
274	Moderate increases in daily step count are associated with reduced IL6 and CRP in women with PCOS. Endocrine Connections, 2018, 7, 1442-1447.	0.8	8
275	The Ready to Reduce Risk (3R) Study for a Group Educational Intervention With Telephone and Text Messaging Support to Improve Medication Adherence for the Primary Prevention of Cardiovascular Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11289.	0.5	4
276	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	1.3	28
277	Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technology Assessment, 2018, 22, 1-160.	1.3	39
278	The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e152.	0.5	1
279	Association Between Lifestyle Factors and the Incidence of Multimorbidity in an Older English Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw146.	1.7	48
280	Considerations when using the activPAL monitor in field-based research with adult populations. Journal of Sport and Health Science, 2017, 6, 162-178.	3.3	303
281	Incident Type 2 diabetes and the effect of early regression to normoglycaemia in a population with impaired glucose regulation. Diabetic Medicine, 2017, 34, 396-404.	1.2	23
282	Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review. Diabetic Medicine, 2017, 34, 14-26.	1.2	174
283	Evaluating the impact of an enhanced primary care diabetes service on diabetes outcomes: A before–after study. Primary Care Diabetes, 2017, 11, 171-177.	0.9	15
284	Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. Postgraduate Medical Journal, 2017, 93, 289-294.	0.9	51
285	Associations of objectively measured moderate-to-vigorous-intensity physical activity and sedentary time with all-cause mortality in a population of adults at high risk of type 2 diabetes mellitus. Preventive Medicine Reports, 2017, 5, 285-288.	0.8	11
286	Cardiovascular risk factors and incident albuminuria in screenâ€detected type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2877.	1.7	2
287	Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trial. BMJ Open, 2017, 7, e013592.	0.8	22
288	Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: a cross-sectional analysis of adults at risk of type 2 diabetes. BMJ Open, 2017, 7, e014267.	0.8	37

#	Article	IF	CITATIONS
289	Reducing sedentary time in adults at risk of type 2 diabetes: process evaluation of the STAND (Sedentary Time ANd Diabetes) RCT. BMC Public Health, 2017, 17, 80.	1.2	9
290	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes, Obesity and Metabolism, 2017, 19, 721-728.	2.2	113
291	Clinical inertiaâ€"Time to reappraise the terminology?. Primary Care Diabetes, 2017, 11, 105-106.	0.9	79
292	Type 2 diabetes. Lancet, The, 2017, 389, 2239-2251.	6.3	1,691
293	Improving diabetes care for people with intellectual disabilities: a qualitative study exploring the perceptions and experiences of professionals in diabetes and intellectual disability services. Journal of Intellectual Disability Research, 2017, 61, 435-449.	1.2	24
294	The effects of supervised exercise training 12–24 months after bariatric surgery on physical function and body composition: a randomised controlled trial. International Journal of Obesity, 2017, 41, 909-916.	1.6	95
295	Associations of moderate-to-vigorous-intensity physical activity and body mass index with glycated haemoglobin within the general population: a cross-sectional analysis of the 2008 Health Survey for England. BMJ Open, 2017, 7, e014456.	0.8	9
296	Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the <scp>LixiLanâ€O</scp> trial testing a titratable fixedâ€ratio combination of insulin glargine/lixisenatide (<scp>iGlarLixi</scp>) vs insulin glargine and lixisenatide monocomponents. Diabetes, Obesity and Metabolism, 2017, 19, 1798-1804.	2.2	22
297	The association between air pollution and type 2 diabetes in a large cross-sectional study in Leicester: The CHAMPIONS Study. Environment International, 2017, 104, 41-47.	4.8	30
298	Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabetic Medicine, 2017, 34, 1219-1227.	1.2	47
299	Exploring why young people with Type 1 diabetes decline structured education with a view to overcoming barriers. Diabetic Medicine, 2017, 34, 1092-1099.	1.2	15
300	Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample. Endocrine Connections, 2017, 6, 323-330.	0.8	34
301	Fitness Moderates Glycemic Responses to Sitting and Light Activity Breaks. Medicine and Science in Sports and Exercise, 2017, 49, 2216-2222.	0.2	33
302	Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese highâ€risk adults: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1732-1739.	2.2	24
303	Type 2 diabetes and glucose intolerance in a population with intellectual disabilities: the STOP diabetes crossâ€sectional screening study. Journal of Intellectual Disability Research, 2017, 61, 668-681.	1.2	15
304	Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T). Diabetes Research and Clinical Practice, 2017, 131, 161-168.	1.1	22
305	Introduction of biosimilar insulins in Europe. Diabetic Medicine, 2017, 34, 1340-1353.	1,2	36
306	Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia, 2017, 60, 1007-1015.	2.9	4

#	Article	IF	Citations
307	Deficiencies in postgraduate training for healthcare professionals who provide diabetes education and support: results from the Diabetes Attitudes, Wishes and Needs (<scp>DAWN</scp> 2) study. Diabetic Medicine, 2017, 34, 1074-1083.	1.2	38
308	Insulin initiation for type 2 diabetes mellitus in primary care. Nature Reviews Endocrinology, 2017, 13, 317-318.	4.3	0
309	Placeboâ€controlled, randomized trial of the addition of onceâ€weekly glucagonâ€like peptideâ€1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (<scp>AWARD</scp> â€9). Diabetes, Obesity and Metabolism, 2017, 19, 1024-1031.	2.2	98
310	Integrated primary care: is this the solution to the diabetes epidemic?. Diabetic Medicine, 2017, 34, 748-750.	1.2	21
311	Risk factors and outcome differences in hypoglycaemiaâ€related hospital admissions: <scp>A</scp> caseâ€control study in <scp>E</scp> ngland. Diabetes, Obesity and Metabolism, 2017, 19, 1371-1378.	2.2	14
312	Barriers and Facilitators to Healthy Lifestyle Changes in Minority Ethnic Populations in the UK: a Narrative Review. Journal of Racial and Ethnic Health Disparities, 2017, 4, 1107-1119.	1.8	47
313	Efficacy and safety of glucagonâ€like peptideâ€l receptor agonists in type 2 diabetes: ⟨scp⟩A⟨ scp⟩ systematic review and mixedâ€treatment comparison analysis. Diabetes, Obesity and Metabolism, 2017, 19, 524-536.	2.2	305
314	Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 1460.	3.8	301
315	Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open, 2017, 7, e016358.	0.8	165
316	Pharmacological control of blood sugar. Anaesthesia and Intensive Care Medicine, 2017, 18, 532-534.	0.1	2
317	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. New England Journal of Medicine, 2017, 377, 2337-2348.	13.9	322
318	Associations of Physical Activity Intensities with Markers of Insulin Sensitivity. Medicine and Science in Sports and Exercise, 2017, 49, 2451-2458.	0.2	14
319	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. Journal of Diabetes and Its Complications, 2017, 31, 1164-1168.	1.2	6
320	Associations Between Anthropometric Measurements and Cardiometabolic Risk Factors in White European and South Asian Adults in the United Kingdom. Mayo Clinic Proceedings, 2017, 92, 925-933.	1.4	16
321	External national validation of the Leicester Selfâ€Assessment score for Type 2 diabetes using data from the English Longitudinal Study of Ageing. Diabetic Medicine, 2017, 34, 1575-1583.	1.2	8
322	Acute effects of exercise on appetite, ad libitum energy intake and appetite-regulatory hormones in lean and overweight/obese men and women. International Journal of Obesity, 2017, 41, 1737-1744.	1.6	70
323	Let's Prevent Diabetes: from idea to implementation. Practical Diabetes, 2017, 34, 55-57.	0.1	2
324	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. Diabetes Research and Clinical Practice, 2017, 132, 137-143.	1.1	0

#	Article	IF	CITATIONS
325	Physical activity and Type 1 diabetes: an underused therapy. Diabetic Medicine, 2017, 34, 1498-1499.	1.2	3
326	Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis. Diabetes Care, 2017, 40, 1588-1596.	4.3	143
327	The prevalence of diabetesâ€specific emotional distress in people with Type 2 diabetes: a systematic review and metaâ€analysis. Diabetic Medicine, 2017, 34, 1508-1520.	1.2	285
328	Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control. Primary Care Diabetes, 2017, 11, 414-420.	0.9	21
329	Comment on: " <scp>S</scp> trengths and <scp>L</scp> imitations of <scp>H</scp> ealthcare <scp>D</scp> atabases in the <scp>E</scp> valuation of <scp>H</scp> ypoglycaemia― Diabetes, Obesity and Metabolism, 2017, 19, 1495-1496.	2.2	0
330	Walking Away from Type 2 diabetes: a cluster randomized controlled trial. Diabetic Medicine, 2017, 34, 698-707.	1.2	66
331	Nonlinear association of BMI with all-cause and cardiovascular mortality in type 2 diabetes mellitus: a systematic review and meta-analysis of 414,587 participants in prospective studies. Diabetologia, 2017, 60, 240-248.	2.9	86
332	Longâ€term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and metaâ€analysis of studies in the postâ€reperfusion era. Diabetes, Obesity and Metabolism, 2017, 19, 364-374.	2.2	29
333	A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin. Diabetes/Metabolism Research and Reviews, 2017, 33, e2858.	1.7	34
334	Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study. European Heart Journal, 2017, 38, 3232-3240.	1.0	168
335	Artificial neural networks in diabetes health care professional education: Effective Diabetes Education Now (EDEN). Practical Diabetes, 2017, 34, 268.	0.1	2
336	Change in Sedentary Time, Physical Activity, Bodyweight, and HbA1c in High-Risk Adults. Medicine and Science in Sports and Exercise, 2017, 49, 1120-1125.	0.2	13
337	The association between depressive symptoms and insulin resistance, inflammation and adiposity in men and women. PLoS ONE, 2017, 12, e0187448.	1.1	41
338	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. Programme Grants for Applied Research, 2017, 5, 1-290.	0.4	12
339	Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. Programme Grants for Applied Research, 2017, 5, 1-316.	0.4	11
340	Managing vascular risk factors among obese quitters with diabetes: how intensive lifestyle intervention and novel pharmacotherapy can work in concert?. British Journal of Diabetes, 2017, 17, 19.	0.1	0
341	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, 2016, 39, 222-230.	4.3	158
342	Developing a Conceptually Equivalent Type 2 Diabetes Risk Score for Indian Gujaratis in the UK. Journal of Diabetes Research, 2016, 2016, 1-9.	1.0	3

#	Article	IF	CITATIONS
343	The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications, 2016, 8, 61.	0.8	35
344	Intensity Thresholds on Raw Acceleration Data: Euclidean Norm Minus One (ENMO) and Mean Amplitude Deviation (MAD) Approaches. PLoS ONE, 2016, 11, e0164045.	1.1	96
345	Sedentary Sphere. Medicine and Science in Sports and Exercise, 2016, 48, 748-754.	0.2	55
346	Effects of glucoseâ€lowering and multifactorial interventions on cardiovascular and mortality outcomes: a metaâ€analysis of randomized control trials. Diabetic Medicine, 2016, 33, 280-289.	1.2	36
347	Guidelines for managing diabetes in Ramadan. Diabetic Medicine, 2016, 33, 1315-1329.	1.2	70
348	Nonexercise Equations to Estimate Fitness in White European and South Asian Men. Medicine and Science in Sports and Exercise, 2016, 48, 854-859.	0.2	8
349	Accuracy of Posture Allocation Algorithms for Thigh- and Waist-Worn Accelerometers. Medicine and Science in Sports and Exercise, 2016, 48, 1085-1090.	0.2	80
350	Raw Accelerometer Data Analysis with GGIR R-package. Medicine and Science in Sports and Exercise, 2016, 48, 1935-1941.	0.2	97
351	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovascular Diabetology, 2016, 15, 102.	2.7	14
352	Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2016, 15, 158.	2.7	58
353	Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Diabetes Research and Clinical Practice, 2016, 118, 12-20.	1.1	8
354	Handbook of Insulin Therapies. , 2016, , .		3
355	Moderate to vigorous physical activity, not sedentary time, is associated with total and regional adiposity in a sample of UK adults at risk of type 2 diabetes. Physiological Measurement, 2016, 37, 1862-1871.	1.2	7
356	Sedentary behaviour as a new behavioural target in the prevention and treatment of type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 213-220.	1.7	67
357	Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, Obesity and Metabolism, 2016, 18, 401-409.	2.2	207
358	Changes in physical activity behaviour and physical function after bariatric surgery: a systematic review and metaâ€analysis. Obesity Reviews, 2016, 17, 250-261.	3.1	116
359	Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1â€year treatâ€ŧoâ€ŧarget trial. Diabetes, Obesity and Metabolism, 2016, 18, 96-99.	2.2	29
360	A community faith centre based screening and educational intervention to reduce the risk of type 2 diabetes: A feasibility study. Diabetes Research and Clinical Practice, 2016, 120, 73-80.	1.1	11

#	Article	IF	Citations
361	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care, 2016, 39, 2026-2035.	4.3	197
362	Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments. Annals of Internal Medicine, 2016, 164, 102.	2.0	70
363	Practical Aspects of Insulin Therapy. , 2016, , 169-209.		0
364	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. Pharmacoeconomics, 2016, 34, 953-966.	1.7	25
365	Basal insulin peglispro versus insulin glargine in insulinâ€naïve type 2 diabetes: <scp>IMAGINE</scp> 2 randomized trial. Diabetes, Obesity and Metabolism, 2016, 18, 1055-1064.	2.2	42
366	Existing Insulin Therapies. , 2016, , 15-53.		2
367	Early Weight Loss with Liraglutide 3.0 mg Predicts $1\hat{a}\in\mathbf{Y}$ ear Weight Loss and is Associated with Improvements in Clinical Markers. Obesity, 2016, 24, 2278-2288.	1.5	88
368	STEPWISE – STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trial. Trials, 2016, 17, 475.	0.7	12
369	Efficacy and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes mellitus: systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2016, 18, 783-794.	2.2	355
370	Impact of Type 1 Diabetes Technology on Family Members/Significant Others of People With Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 824-830.	1.3	52
371	New drug treatments versus structured education programmes for type 2 diabetes: comparing cost-effectiveness. Lancet Diabetes and Endocrinology,the, 2016, 4, 557-559.	5.5	7
372	Long terms trends of multimorbidity and association with physical activity in older English population. International Journal of Behavioral Nutrition and Physical Activity, 2016, 13, 8.	2.0	116
373	Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet Diabetes and Endocrinology,the, 2016, 4, 677-685.	5.5	60
374	Optimizing management of glycaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 397-411.	2.2	10
375	A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. Preventive Medicine, 2016, 84, 48-56.	1.6	83
376	Type 2 diabetes: lifetime risk of advancing from prediabetes. Lancet Diabetes and Endocrinology,the, 2016, 4, 5-6.	5.5	2
377	Development of a lifestyle intervention using the MRC framework for diabetes prevention in people with impaired glucose regulation. Journal of Public Health, 2016, 38, 493-501.	1.0	23
378	A retrospective evaluation of the NHS Health Check Programme in a multi-ethnic population. Journal of Public Health, 2016, 38, 534-542.	1.0	6

#	Article	IF	Citations
379	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. Diabetes Care, 2016, 39, 130-138.	4.3	229
380	ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction, 2016, 31, 926-937.	0.4	916
381	A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes. Diabetes Research and Clinical Practice, 2016, 113, 1-13.	1.1	38
382	New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal, 2016, 92, 152-164.	0.9	22
383	Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal, 2016, 92, 63-69.	0.9	360
384	Engagement, Retention, and Progression to Type 2 Diabetes: A Retrospective Analysis of the Cluster-Randomised "Let's Prevent Diabetes" Trial. PLoS Medicine, 2016, 13, e1002078.	3.9	21
385	Use of SGLT2 inhibitors during Ramadan: a survey of physicians' views and practical guidance. British Journal of Diabetes, 2016, 16, 20.	0.1	10
386	Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. British Journal of Diabetes, 2016, 16, 128.	0.1	5
387	Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e270.	2.1	57
388	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Health Technology Assessment, 2016, 20, 1-86.	1.3	12
389	Costâ€effectiveness of intensive multifactorial treatment compared with routine care for individuals with screenâ€detected Type 2 diabetes: analysis of the ADDITION ―UK cluster―andomized controlled trial. Diabetic Medicine, 2015, 32, 907-919.	1.2	19
390	The effects of highâ€intensity interval training on glucose regulation and insulin resistance: a metaâ€analysis. Obesity Reviews, 2015, 16, 942-961.	3.1	387
391	Medication burden in the first 5â€years following diagnosis of type 2 diabetes: findings from the∢i>ADDITION-UK∢/i>trial cohort. BMJ Open Diabetes Research and Care, 2015, 3, e000075.	1.2	8
392	PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. Trials, 2015, 16, 289.	0.7	22
393	Physical activity as a determinant of fasting and 2â€h postâ€challenge glucose: a prospective cohort analysis of the <scp>NAVIGATOR</scp> trial. Diabetic Medicine, 2015, 32, 1090-1096.	1.2	13
394	Providing NHS staff with height-adjustable workstations and behaviour change strategies to reduce workplace sitting time: protocol for the Stand More AT (SMArT) Work cluster randomised controlled trial. BMC Public Health, 2015, 15, 1219.	1.2	25
395	Associations of mutually exclusive categories of physical activity and sedentary time with markers of cardiometabolic health in English adults: a cross-sectional analysis of the Health Survey for England. BMC Public Health, 2015, 16, 25.	1.2	81
396	Associations of Sedentary Time with Fat Distribution in a High-Risk Population. Medicine and Science in Sports and Exercise, 2015, 47, 1727-1734.	0.2	30

#	Article	IF	CITATIONS
397	Emerging epidemic and challenges of Type 2 diabetes in young adults. Diabetes Management, 2015, 5, 473-483.	0.5	9
398	Comment on Nolan et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes 2015;64:673–686. Diabetes, 2015, 64, e35-e36.	0.3	3
399	Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. Diabetic Medicine, 2015, 32, 407-413.	1.2	74
400	Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE, 2015, 10, e0126427.	1.1	161
401	The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS ONE, 2015, 10, e0126769.	1.1	127
402	Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE, 2015, 10, e0135702.	1.1	21
403	Serum Potassium and Glucose Regulation in the ADDITION-Leicester Screening Study. Journal of Diabetes Research, 2015, 2015, 1-4.	1.0	1
404	Association between direct measurement of active serum calcium and risk of type 2 diabetes mellitus: A prospective study. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 562-568.	1.1	9
405	Objectively measured sedentary time and associations with insulin sensitivity: Importance of reallocating sedentary time to physical activity. Preventive Medicine, 2015, 76, 79-83.	1.6	57
406	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment, 2015, 19, 1-80.	1.3	24
407	Effect of the PPARG2 Pro12Ala Polymorphism on Associations of Physical Activity and Sedentary Time with Markers of Insulin Sensitivity in Those with an Elevated Risk of Type 2 Diabetes. PLoS ONE, 2015, 10, e0124062.	1.1	10
408	Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care, 2015, 38, 1449-1455.	4.3	214
409	Differences in levels of physical activity between White and South Asian populations within a healthcare setting: impact of measurement type in a cross-sectional study. BMJ Open, 2015, 5, e006181.	0.8	25
410	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 2015, 5, e007901.	0.8	7
411	Association between undiagnosed hypertension and microalbuminuria in South Asians without known diabetes. Journal of Human Hypertension, 2015, 29, 185-189.	1.0	4
412	Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 2015, 107, 320-331.	1.1	112
413	The impact of a programme to improve quality of care for people with type 2 diabetes on hard to reach groups: The GEDAPS study. Primary Care Diabetes, 2015, 9, 211-218.	0.9	17
414	Survival in South Asian and White European patients after acute myocardial infarction. Heart, 2015, 101, 630-636.	1.2	10

#	Article	lF	CITATIONS
415	The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2015, 31, 1693-1702.	0.9	16
416	Is the number of fast-food outlets in the neighbourhood related to screen-detected type 2 diabetes mellitus and associated risk factors?. Public Health Nutrition, 2015, 18, 1698-1705.	1.1	41
417	A study protocol for a pilot randomised trial of a structured education programme for the self-management of Type 2 diabetes for adults with intellectual disabilities. Trials, 2015, 16, 148.	0.7	16
418	Safety and effectiveness of nonâ€insulin glucoseâ€lowering agents in the treatment of people with type 2 diabetes who observe <scp>R</scp> amadan: a systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2015, 17, 639-648.	2.2	30
419	Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. Clinical Endocrinology, 2015, 83, 542-549.	1.2	32
420	Cardiorespiratory fitness and risk of type 2 diabetes mellitus: A 23-year cohort study and a meta-analysis of prospective studies. Atherosclerosis, 2015, 243, 131-137.	0.4	68
421	Explaining engagement in self-monitoring among participants of the DESMOND Self-monitoring Trial: a qualitative interview study. Family Practice, 2015, 32, 596-602.	0.8	10
422	A cluster randomised controlled trial to investigate the effectiveness and cost effectiveness of the $\hat{a}\in G$ intervention: a study protocol. BMC Public Health, 2015, 15, 526.	1.2	27
423	Inverse association between fasting plasma glucose and risk of ventricular arrhythmias. Diabetologia, 2015, 58, 1797-1802.	2.9	10
424	Selfâ€monitoring of blood glucose versus selfâ€monitoring of urine glucose in adults with newly diagnosed Type 2 diabetes receiving structured education: a cluster randomized controlled trial. Diabetic Medicine, 2015, 32, 414-422.	1.2	16
425	Concerns and perceptions about necessity in relation to insulin therapy in an ethnically diverse <scp>UK</scp> population with Type 2 diabetes: a qualitative study focusing mainly on people of South Asian origin. Diabetic Medicine, 2015, 32, 635-644.	1.2	15
426	Current management of diabetes mellitus and future directions in care. Postgraduate Medical Journal, 2015, 91, 612-621.	0.9	54
427	Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2015, 314, 687.	3.8	707
428	Using an interactive DVD about type 2 diabetes and insulin therapy in a UK South Asian community and in patient education and healthcare provider training. Patient Education and Counseling, 2015, 98, 1123-1130.	1.0	11
429	Diabetes in people with intellectual disabilities: A systematic review of the literature. Research in Developmental Disabilities, 2015, 47, 352-374.	1.2	57
430	Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 2015, 38, 316-322.	4.3	276
431	Development and validation of a cost–utility model for TypeÂ1 diabetes mellitus. Diabetic Medicine, 2015, 32, 1023-1035.	1.2	11
432	A Randomised Controlled Trial to Reduce Sedentary Time in Young Adults at Risk of Type 2 Diabetes Mellitus: Project STAND (Sedentary Time ANd Diabetes). PLoS ONE, 2015, 10, e0143398.	1.1	56

#	Article	IF	Citations
433	Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. British Journal of Diabetes and Vascular Disease, 2015, 15, 65.	0.6	48
434	A Text-Messaging and Pedometer Program to Promote Physical Activity in People at High Risk of Type 2 Diabetes: The Development of the PROPELS Follow-On Support Program. JMIR MHealth and UHealth, 2015, 3, e105.	1.8	34
435	The Effectiveness of Screening for Diabetes and Cardiovascular Disease Risk Factors in a Community Pharmacy Setting. PLoS ONE, 2014, 9, e91157.	1.1	83
436	Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice, 2014, 64, e208-e216.	0.7	11
437	Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis. Diabetes Care 2014;37:922–933. Diabetes Care, 2014, 37, 1775-1776.	4.3	14
438	The association between neighbourhood greenspace and type 2 diabetes in a large cross-sectional study. BMJ Open, 2014, 4, e006076.	0.8	89
439	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology, 2014, 40, 64-74.	1.4	106
440	Kaleidoscope model of diabetes care: time for a rethink?. Diabetic Medicine, 2014, 31, 522-530.	1.2	27
441	Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. Journal of Diabetes and Its Complications, 2014, 28, 880-886.	1.2	42
442	Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screenâ€detected diabetes? Results from the ADDITIONâ€Europe cluster randomized trial . Diabetic Medicine, 2014, 31, 647-656.	1.2	20
443	Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26â€week randomized, openâ€label, treatâ€toâ€target nonâ€inferiority trial. Diabetes Obesity and Metabolism, 2014, 16, 922-930.	,2.2	47
444	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 2015-2023.	4.3	56
445	Prevalence and characteristics in coding, classification and diagnosis of diabetes in primary care. Postgraduate Medical Journal, 2014, 90, 13-17.	0.9	24
446	Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms. European Heart Journal Cardiovascular Imaging, 2014, 15, 1263-1269.	0.5	58
447	Adverse Responses and Physical Activity. Medicine and Science in Sports and Exercise, 2014, 46, 1617-1623.	0.2	12
448	Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417. Diabetes Care, 2014, 37, e114-e114.	4.3	1
449	Identifying effective pathways in a successful continuous quality improvement programme: the <scp>GEDAPS</scp> study. Journal of Evaluation in Clinical Practice, 2014, 20, 1137-1143.	0.9	2
450	External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice, 2014, 104, 451-458.	1.1	5

#	Article	IF	Citations
451	The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes, Obesity and Metabolism, 2014, 16, 237-247.	2.2	14
452	Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Primary Care Diabetes, 2014, 8, 57-63.	0.9	12
453	TypeÂ2 diabetes mellitus and obesity in young adults: the extreme phenotype with early cardiovascular dysfunction. Diabetic Medicine, 2014, 31, 794-798.	1.2	30
454	Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. Diabetes Research and Clinical Practice, 2014, 104, 281-287.	1.1	45
455	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet, The, 2014, 383, 1059-1066.	6.3	186
456	A <scp>M</scp> editerranean diet improves <scp>H</scp> b <scp>A</scp> 1c but not fasting blood glucose compared to alternative dietary strategies: a network metaâ€analysis. Journal of Human Nutrition and Dietetics, 2014, 27, 280-297.	1.3	49
457	Diabetes self-management education: acceptability of using trained lay educators. Postgraduate Medical Journal, 2014, 90, 638-642.	0.9	16
458	Glycaemic management of type 2 diabetes. Medicine, 2014, 42, 711-717.	0.2	1
459	A randomized controlled trial comparing the <scp>GLP</scp> â€1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes, Obesity and Metabolism, 2014, 16, 527-536.	2.2	52
460	Clinical characteristics of people experiencing biochemical hypoglycaemia during an oral glucose tolerance test: Cross-sectional analyses from a UK multi-ethnic population. Diabetes Research and Clinical Practice, 2014, 104, 427-434.	1.1	13
461	Pharmacological control of blood sugar. Anaesthesia and Intensive Care Medicine, 2014, 15, 470-472.	0.1	O
462	Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations. Diabetes Care, 2014, 37, 922-933.	4.3	448
463	Risk assessment tools for detecting those with pre-diabetes: A systematic review. Diabetes Research and Clinical Practice, 2014, 105, 1-13.	1.1	41
464	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. Metabolism: Clinical and Experimental, 2014, 63, 554-561.	1.5	37
465	Body Mass Index and Waist Circumference Cut-Points in Multi-Ethnic Populations from the UK and India: The ADDITION-Leicester, Jaipur Heart Watch and New Delhi Cross-Sectional Studies. PLoS ONE, 2014, 9, e90813.	1.1	39
466	Psychometric validation of the Self-Care Inventory-Revised (SCI-R) in UK adults with type 2 diabetes using data from the AT.LANTUS Follow-on study. Health and Quality of Life Outcomes, 2013, 11, 24.	1.0	16
467	Efficacy and safety over 26Âweeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia, 2013, 56, 1503-1511.	2.9	50
468	Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care, 2013, 36, 1368-1376.	4.3	69

#	Article	IF	CITATIONS
469	Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia, 2013, 56, 1489-1493.	2.9	191
470	Associations of objectively measured sedentary behaviour and physical activity with markers of cardiometabolic health. Diabetologia, 2013, 56, 1012-1020.	2.9	268
471	Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. Diabetologia, 2013, 56, 2367-2377.	2.9	18
472	Insulin degludec: overview of a novel ultra longâ€acting basal insulin. Diabetes, Obesity and Metabolism, 2013, 15, 301-309.	2.2	58
473	Diabetes Attitudes Wishes and Needs 2 (DAWN2): A multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Research and Clinical Practice, 2013, 99, 174-184.	1.1	195
474	Clinical Inertia in People With Type 2 Diabetes. Diabetes Care, 2013, 36, 3411-3417.	4.3	508
475	DAWN2 study findings: psychosocial support and structured education need to be more widespread. Practical Diabetes, 2013, 30, 239-240.	0.1	2
476	Identifying people with type 2 diabetes and those at risk: Lessons from the Measure Your Waist (MY-WAIST) mixed-methods study in UK primary care. Primary Care Diabetes, 2013, 7, 261-267.	0.9	2
477	Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: A retrospective study. Primary Care Diabetes, 2013, 7, 159-165.	0.9	39
478	The development and validation of the Portuguese risk score for detecting type 2 diabetes and impaired fasting glucose. Primary Care Diabetes, 2013, 7, 11-18.	0.9	14
479	Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20â€year retrospective cohort study. Clinical Endocrinology, 2013, 78, 926-934.	1.2	156
480	Diabetes prevention: NICE opportunity for implementing programmes in the realâ€world setting. Diabetic Medicine, 2013, 30, 1-2.	1.2	6
481	The impact of diet and lifestyle management strategies for obstructive sleep apnoea in adults: a systematic review and meta-analysis of randomised controlled trials. Sleep and Breathing, 2013, 17, 925-935.	0.9	81
482	Realâ€world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabetic Medicine, 2013, 30, 512-524.	1.2	228
483	South Asian individuals at high risk of type 2 diabetes have lower plasma vitamin C levels than white Europeans. Journal of Nutritional Science, 2013, 2, e21.	0.7	3
484	Effect of physical activity measurement type on the association between walking activity and glucose regulation in a high-risk population recruited from primary care. International Journal of Epidemiology, 2013, 42, 533-540.	0.9	18
485	Evaluation of the Healthy LifeCheck programme: a vascular risk assessment service for community pharmacies in Leicester city, UK. Journal of Public Health, 2013, 35, 440-446.	1.0	12
486	All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. British Journal of Diabetes and Vascular Disease, 2013, 13, 22-30.	0.6	1

#	Article	IF	Citations
487	Diagnostic performance of using one- or two-HbA1c cut-point strategies to detect undiagnosed type 2 diabetes and impaired glucose regulation within a multi-ethnic population. Diabetes and Vascular Disease Research, 2013, 10, 84-92.	0.9	7
488	Prescribing in pregnancy for women with diabetes: use of potential teratogenic drugs and contraception. Diabetic Medicine, 2013, 30, 457-463.	1.2	11
489	Systematic review of the development, implementation and availability of smartâ€phone applications for assessing TypeÂ2 diabetes risk. Diabetic Medicine, 2013, 30, 758-760.	1.2	9
490	Prevalence of diabetes and impaired glucose metabolism in younger â€~at risk' <scp>UK</scp> adults: insights from the <scp>STAND</scp> programme of research. Diabetic Medicine, 2013, 30, 671-675.	1.2	26
491	Biomarker Research in Glucose Disorders: Current Concepts and Clinical Applications. Journal of Diabetes Research, 2013, 2013, 1-2.	1.0	0
492	Adipocytokine Associations with Insulin Resistance in British South Asians. Journal of Diabetes Research, 2013, 2013, 1-7.	1.0	6
493	The association between body mass index and healthâ€related quality of life: influence of ethnicity on this relationship. Diabetes, Obesity and Metabolism, 2013, 15, 342-348.	2.2	19
494	Selfâ€titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes, Obesity and Metabolism, 2013, 15, 690-700.	2.2	39
495	Fruit and vegetable intake and the association with glucose parameters: a cross-sectional analysis of the Let's Prevent Diabetes Study. European Journal of Clinical Nutrition, 2013, 67, 12-17.	1.3	46
496	Authors' response. British Journal of General Practice, 2013, 63, 236.1-236.	0.7	0
497	Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans. PLoS ONE, 2013, 8, e55580.	1.1	26
498	Sedentary Time and Markers of Chronic Low-Grade Inflammation in a High Risk Population. PLoS ONE, 2013, 8, e78350.	1.1	148
499	Diagnosing type 2 diabetes and identifying high-risk individuals using the new glycated haemoglobin (HbA1c) criteria. British Journal of General Practice, 2013, 63, e165-e167.	0.7	17
500	Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrology Dialysis Transplantation, 2012, 27, 1860-1866.	0.4	60
501	Investigating Endothelial Activation and Oxidative Stress in relation to Glycaemic Control in a Multiethnic Population. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	9
502	Association of Sedentary Behaviour with Metabolic Syndrome: A Meta-Analysis. PLoS ONE, 2012, 7, e34916.	1.1	388
503	Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ, The, 2012, 344, e2333-e2333.	3.0	268
504	Treatment evaluation of liraglutide in type 2 diabetes. Expert Opinion on Biological Therapy, 2012, 12, 1551-1556.	1.4	6

#	Article	IF	CITATIONS
505	Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2012, 8, 363-373.	4.3	108
506	Primary prevention of cardiovascular disease using validated risk scores: A systematic review. Journal of the Royal Society of Medicine, 2012, 105, 348-356.	1.1	31
507	Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 1986-1993.	4.3	58
508	Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes. Diabetes Care, 2012, 35, 2174-2181.	4.3	69
509	Dietary Recommendations for the Prevention of Type 2 diabetes: What Are They Based on?. Journal of Nutrition and Metabolism, 2012, 2012, 1-6.	0.7	13
510	Is admission blood glucose concentration a more powerful predictor of mortality after myocardial infarction than diabetes diagnosis? A retrospective cohort study. BMJ Open, 2012, 2, e001596.	0.8	19
511	Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors. Clinical Practice (London, England), 2012, 9, 23-38.	0.1	0
512	Insulin initiation and management in people with Type $\hat{a} \in f2$ diabetes in an ethnically diverse population: the healthcare provider perspective. Diabetic Medicine, 2012, 29, 1311-1316.	1.2	27
513	Generic and diabetesâ€specific wellâ€being in the AT.LANTUS Followâ€on study: further psychometric validation of the Wâ€BQ28 indicates its utility in research and clinical practice in Type 2 diabetes in the UK. Diabetic Medicine, 2012, 29, e345-53.	1.2	8
514	An Investigation into the Relationship Between Sleep-Disordered Breathing, the Metabolic Syndrome, Cardiovascular Risk Profiles, and Inflammation Between South Asians and Caucasians Residing in the United Kingdom. Metabolic Syndrome and Related Disorders, 2012, 10, 152-158.	0.5	13
515	Self-Reported Sitting Time and Markers of Inflammation, Insulin Resistance, and Adiposity. American Journal of Preventive Medicine, 2012, 42, 1-7.	1.6	116
516	A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study. Diabetes Research and Clinical Practice, 2012, 97, 505-513.	1.1	60
517	Does self monitoring of blood glucose as opposed to urinalysis provide additional benefit in patients newly diagnosed with type 2 diabetes receiving structured education? The DESMOND SMBG randomised controlled trial protocol. BMC Family Practice, 2012, 13, 18.	2.9	10
518	Walking away from type 2 diabetes: trial protocol of a cluster randomised controlled trial evaluating a structured education programme in those at high risk of developing type 2 diabetes. BMC Family Practice, 2012, 13, 46.	2.9	48
519	Letâ \in [™] s prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovascular Diabetology, 2012, 11, 56.	2.7	33
520	A cluster randomized controlled trial of the effectiveness and cost-effectiveness of Intermediate Care Clinics for Diabetes (ICCD): study protocol for a randomized controlled trial. Trials, 2012, 13, 164.	0.7	8
521	Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screenâ€detected diabetes? Findings from the ADDITIONâ€Europe clusterâ€randomized trial. Diabetic Medicine, 2012, 29, e409-16.	1.2	15
522	Association of Sitting Time and Physical Activity With CKD: A Cross-sectional Study in Family Practices. American Journal of Kidney Diseases, 2012, 60, 583-590.	2.1	48

#	Article	IF	Citations
523	Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia, 2012, 55, 3238-3244.	2.9	34
524	Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia, 2012, 55, 2895-2905.	2.9	1,371
525	Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Medicine, 2012, 10, 152.	2.3	20
526	The Association of the Triglyceride-to-HDL Cholesterol Ratio with Insulin Resistance in White European and South Asian Men and Women. PLoS ONE, 2012, 7, e50931.	1.1	29
527	Influences on the uptake of diabetes screening: a qualitative study in primary care. British Journal of General Practice, 2012, 62, e204-e211.	0.7	46
528	Obesity and chronic disease in younger people: an unfolding crisis. British Journal of General Practice, 2012, 62, 4-5.	0.7	11
529	A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes. Diabetes Therapy, 2012, 3, 1-16.	1.2	5
530	Patientâ€reported outcomes in trials of incretinâ€based therapies in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2012, 14, 882-892.	2.2	49
531	Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as addâ€on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Medicine, 2012, 29, 313-320.	1.2	46
532	Intensive multifactorial intervention improves modelled coronary heart disease risk in screenâ€detected Type 2 diabetes mellitus: a cluster randomized controlled trial. Diabetic Medicine, 2012, 29, 531-540.	1.2	29
533	Validity of selfâ€assessed waist circumference in a multiâ€ethnic UK population. Diabetic Medicine, 2012, 29, 404-409.	1.2	21
534	Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. Diabetologia, 2012, 55, 959-966.	2.9	68
535	What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review Health Technology Assessment, 2012, 16, iii-xiv, 1-195.	1.3	45
536	Liraglutide improves treatment satisfaction in people with Typeâ \in f2 diabetes compared with sitagliptin, each as an add on to metformin. Diabetic Medicine, 2011, 28, 333-337.	1.2	49
537	Type 2 diabetes in younger adults: Clinical characteristics, diabetes-related complications and management of risk factors. Primary Care Diabetes, 2011, 5, 57-62.	0.9	19
538	Type 2 diabetes and cardiovascular disease in South Asians. Primary Care Diabetes, 2011, 5, 45-56.	0.9	177
539	Characteristics, complications and management of a large multiethnic cohort of younger adults with type 2 diabetes. Primary Care Diabetes, 2011, 5, 245-250.	0.9	27
540	Pharmacological control of blood sugar. Anaesthesia and Intensive Care Medicine, 2011, 12, 473-475.	0.1	0

#	Article	IF	Citations
541	Sedentary Behavior. American Journal of Preventive Medicine, 2011, 40, e33-e34.	1.6	35
542	Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice. Diabetes Research and Clinical Practice, 2011, 91, 280-285.	1.1	6
543	Stand up for your health: Is it time to rethink the physical activity paradigm?. Diabetes Research and Clinical Practice, 2011, 93, 292-294.	1.1	38
544	Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: The Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research and Clinical Practice, 2011, 93, 328-336.	1.1	41
545	Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet, The, 2011, 378, 156-167.	6.3	406
546	Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 207-220.	2.2	61
547	The association between anxiety and measures of glycaemia in a populationâ€based diabetes screening programme. Diabetic Medicine, 2011, 28, 785-788.	1.2	4
548	The Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2â€∫years?. Diabetic Medicine, 2011, 28, 1268-1271.	1.2	44
549	Screening for Type 2 diabetes. Lessons from the ADDITIONâ€Europe study. Diabetic Medicine, 2011, 28, 1416-1424.	1.2	53
550	One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. International Journal of Clinical Practice, 2011, 65, 397-407.	0.8	221
551	The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. International Journal of Clinical Practice, 2011, 65, 1132-1140.	0.8	90
552	Rationale and study design for a randomised controlled trial to reduce sedentary time in adults at risk of type 2 diabetes mellitus: project stand (Sedentary Time ANd diabetes). BMC Public Health, 2011, 11, 908.	1.2	39
553	Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia, 2011, 54, 2237-2246.	2.9	55
554	The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data. Trials, 2011, 12, 107.	0.7	10
555	Diabetes myths and legends: the Iliad and the Odyssey. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 37.	0.2	0
556	Liraglutide for type 2 diabetes mellitus. Expert Opinion on Biological Therapy, 2011, 11, 951-959.	1.4	6
557	Comparison of illness representations dimensions and illness representation clusters in predicting outcomes in the first year following diagnosis of type 2 diabetes: Results from the DESMOND trial. Psychology and Health, 2011, 26, 321-335.	1.2	42
558	The NICE Diabetes in Adults Quality Standards. British Journal of Diabetes and Vascular Disease, 2011, 11, 225-227.	0.6	2

#	Article	IF	CITATIONS
559	Association of cardiac and non-cardiac chronic disease comorbidity on glycaemic control in a multi-ethnic population with type 1 and type 2 diabetes. Postgraduate Medical Journal, 2011, 87, 763-768.	0.9	13
560	An update on exenatide, a novel therapeutic option for patients with type 2 diabetes. Drugs of Today, 2011, 47, 839.	0.7	4
561	Defining Obesity Cut-Off Points for Migrant South Asians. PLoS ONE, 2011, 6, e26464.	1.1	95
562	The prevalence of depressive symptoms in a white European and South Asian population with impaired glucose regulation and screenâ€detected Type 2 diabetes mellitus: a comparison of two screening tools. Diabetic Medicine, 2010, 27, 896-905.	1.2	11
563	Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia, 2010, 53, 1190-1198.	2.9	96
564	Glycaemic management of type 2 diabetes. Medicine, 2010, 38, 618-625.	0.2	2
565	The association between depression and healthâ€related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes/Metabolism Research and Reviews, 2010, 26, 75-89.	1.7	138
566	Rationale and design of the ADDITION-Leicester study, a systematic screening programme and Randomised Controlled Trial of multi-factorial cardiovascular risk intervention in people with Type 2 Diabetes Mellitus detected by screening. Trials, 2010, 11, 16.	0.7	71
567	How can structured selfâ€management patient education improve outcomes in people with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2010, 12, 12-19.	2.2	80
568	Searching for the right outcome? A systematic review and metaâ€analysis of controlled trials using carotid intimaâ€media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes, Obesity and Metabolism, 2010, 12, 124-132.	2.2	16
569	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes, Obesity and Metabolism, 2010, 12, 474-484.	2.2	25
570	Effect of insulin glargine on glycaemic control and weight in obese and nonâ€obese people with type 2 diabetes: data from the AT.LANTUS trial. Diabetes, Obesity and Metabolism, 2010, 12, 683-688.	2.2	13
571	The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus. Diabetic Medicine, 2010, 27, 762-769.	1.2	54
572	Depressive symptoms in the first year from diagnosis of Type 2 diabetes: results from the DESMOND trial. Diabetic Medicine, 2010, 27, 965-967.	1.2	32
573	The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabetic Medicine, 2010, 27, 887-895.	1.2	151
574	The effect of increased ambulatory activity on markers of chronic lowâ€grade inflammation: evidence from the PREPARE programme randomized controlled trial. Diabetic Medicine, 2010, 27, 1256-1263.	1.2	19
575	Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study. Vascular Health and Risk Management, 2010, 6, 837.	1.0	16
576	A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. Diabetes Care, 2010, 33, 1176-1178.	4.3	145

#	Article	IF	CITATIONS
577	Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation?. Postgraduate Medical Journal, 2010, 86, 656-662.	0.9	38
578	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	13.9	588
579	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1463-1476.	13.9	430
580	Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ: British Medical Journal, 2010, 341, c4093-c4093.	2.4	168
581	Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ: British Medical Journal, 2010, 341, c4229-c4229.	2.4	584
582	Screening for the metabolic syndrome using simple anthropometric measurements in south Asian and white Europeans: A population-based screening study. The Leicester Ethnic Atherosclerosis and Diabetes Risk (LEADER) Study. Primary Care Diabetes, 2010, 4, 25-32.	0.9	22
583	Clinical inertia in management of T2DM. Primary Care Diabetes, 2010, 4, 203-207.	0.9	79
584	The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Research and Clinical Practice, 2010, 90, 100-108.	1.1	55
585	Levels of physical activity and relationship with markers of diabetes and cardiovascular disease risk in 5474 white European and South Asian adults screened for type 2 diabetes. Preventive Medicine, 2010, 51, 290-294.	1.6	61
586	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, The, 2010, 375, 1447-1456.	6.3	534
587	Type 2 diabetes in younger adults: the emerging UK epidemic. Postgraduate Medical Journal, 2010, 86, 711-718.	0.9	56
588	Unanswered questions over NHS health checks. BMJ: British Medical Journal, 2010, 342, c6312-c6312.	2.4	23
589	The Prevalence of Depression in White-European and South-Asian People with Impaired Glucose Regulation and Screen-Detected Type 2 Diabetes Mellitus. PLoS ONE, 2009, 4, e7755.	1.1	29
590	New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal, 2009, 85, 257-267.	0.9	38
591	Epicardial Adipose Tissue as a Source of Nuclear Factor-κB and c-Jun N-Terminal Kinase Mediated Inflammation in Patients with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 261-267.	1.8	114
592	Waist circumference measurement: knowledge, attitudes and barriers in patients and practitioners in a multi-ethnic population. Family Practice, 2009, 26, 365-371.	0.8	39
593	The role of physical activity in the management of type 2 diabetes mellitus. Postgraduate Medical Journal, 2009, 85, 129-133.	0.9	6
594	Effectiveness of a Pragmatic Education Program Designed to Promote Walking Activity in Individuals With Impaired Glucose Tolerance. Diabetes Care, 2009, 32, 1404-1410.	4.3	169

#	Article	IF	CITATIONS
595	Prevalence of diagnosed depression in South Asian and white European people with type 1 and type 2 diabetes mellitus in a UK secondary care population. Postgraduate Medical Journal, 2009, 85, 238-243.	0.9	30
596	Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgraduate Medical Journal, 2009, 85, 219-222.	0.9	31
597	Preventing type 2 diabetes: can we make the evidence work?. Postgraduate Medical Journal, 2009, 85, 475-480.	0.9	23
598	The National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for Leicestershire, Northamptonshire and Rutland (LNR): a programme protocol. Implementation Science, 2009, 4, 72.	2.5	25
599	Exenatide compared with longâ€acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Longâ€Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism, 2009, 11, 1153-1162.	2.2	141
600	The response of circulating levels of the interleukin-6/interleukin-6 receptor complex to exercise in young men. Cytokine, 2009, 47, 98-102.	1.4	26
601	Is having a family history of type 2 diabetes or cardiovascular disease a predictive factor for metabolic syndrome?. Primary Care Diabetes, 2009, 3, 49-56.	0.9	13
602	Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine, 2009, 361, 1736-1747.	13.9	608
603	The development of a diabetes prevention programme for a South Asian population: translating evidence and theory into practice., 2009,, 233-249.		1
604	Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: A randomized controlled trial. Patient Education and Counseling, 2008, 73, 264-271.	1.0	44
605	A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 2008, 51, 408-416.	2.9	424
606	When to biopsy a foot ulcer? Seven cases of malignant melanoma presenting as foot ulcers. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 5-8.	0.2	6
607	Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*. Diabetes, Obesity and Metabolism, 2008, 10, 959-969.	2.2	205
608	Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Diabetes, Obesity and Metabolism, 2008, 10, 42-49.	2.2	16
609	Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial*. Diabetes, Obesity and Metabolism, 2008, 10, 387-399.	2.2	60
610	Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity and Metabolism, 2008, 10, 545-555.	2.2	222
611	â€~Educator talk' and patient change: some insights from the DESMOND (Diabetes Education and Self) Tj E7	ГQq1 1 0.7 1.2	784314 rgBT 52
612	Biomedical, lifestyle and psychosocial characteristics of people newly diagnosed with Type 2 diabetes: baseline data from the DESMOND randomized controlled trial. Diabetic Medicine, 2008, 25, 1454-1461.	1.2	31

#	Article	lF	Citations
613	Diabetic emergencies in acute/critical care. Foundation Years, 2008, 4, 230-233.	0.0	0
614	Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia. Diabetes Technology and Therapeutics, 2008, 10, 273-277.	2.4	42
615	Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Research and Clinical Practice, 2008, 79, 368-375.	1.1	35
616	Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ: British Medical Journal, 2008, 336, 1180-1185.	2.4	239
617	Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ: British Medical Journal, 2008, 336, 491-495.	2.4	617
618	Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine, 2007, 357, 1716-1730.	13.9	651
619	Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes, Obesity and Metabolism, 2007, 9, 706-713.	2.2	19
620	A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabetic Medicine, 2007, 24, 714-719.	1.2	16
621	The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia, 2007, 50, 1116-1126.	2.9	123
622	The prevalence of co-morbid depression in adults with TypeÂ2 diabetes: a systematic review and meta-analysis. Diabetic Medicine, 2006, 23, 1165-1173.	1.2	1,002
623	Diabetes education and self-management for ongoing and newly diagnosed (DESMOND): Process modelling of pilot study. Patient Education and Counseling, 2006, 64, 369-377.	1.0	122
624	Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2006, 7, 1357-1371.	0.9	15
625	A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care, 2006, 29, 1269-1274.	4.3	605
626	Post-prandial hyperglycaemia and prevention of cardiovascular disease. Diabetic Medicine, 2005, 22, 6-9.	1.2	12
627	Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care, 2005, 28, 1282-1288.	4.3	288
628	Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabetic Medicine, 2004, 21, 403-414.	1.2	67
629	Evaluation of admissions and management of diabetic ketoacidosis in a large teaching hospital. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2004, 21, 149-153.	0.2	10
630	The prevention of type 2 diabetes mellitus. Clinical Medicine, 2003, 3, 470-474.	0.8	3

#	Article	IF	CITATIONS
631	Mapping "Region―in Canadian Medical Historv: The Case of British Columbia. Canadian Bulletin of Medical History = Bulletin Canadien D'histoire De La Médecine, 2000, 17, 73-92.	0.0	13
632	Insulin Levels following Islet- Cell Autotransplantation. Clinical Science, 1997, 93, 14P-14P.	0.0	0
633	Total one-stage repair of aortopulmonary window and interrupted aortic arch in a neonate. Pediatric Cardiology, 1996, 17, 122-124.	0.6	10
634	A new method for rapid, percutaneous, sheathless insertion of the intra-aortic balloon. The British Journal of Clinical Practice, 1996, 50, 226-7.	0.2	0
635	Total One-Stage Repair of Aortopulmonary Window and Interrupted Aortic Arch in a Neonate. Pediatric Cardiology, 1996, 17, 122-124.	0.6	0
636	Extracorporeal membrane oxygenation for the treatment of massive pulmonary embolism. Annals of Thoracic Surgery, 1995, 60, 1801-1803.	0.7	46
637	Framework to aid analysis and interpretation of ongoing COVID-19 research. Wellcome Open Research, 0, 5, 208.	0.9	10